Cargando…
Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report
Clinical trials of chimeric antigen receptor (CAR) T cells in hematologic malignancy associate remissions with two profiles of CAR T cell proliferation kinetics, which differ based upon costimulatory domain. Additional T cell intrinsic factors that influence or predict clinical response remain uncle...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320786/ https://www.ncbi.nlm.nih.gov/pubmed/30572564 http://dx.doi.org/10.3390/ijms19124118 |
_version_ | 1783385284987060224 |
---|---|
author | Funk, Christopher Ronald Petersen, Christopher T. Jagirdar, Neera Ravindranathan, Sruthi Jaye, David L. Flowers, Christopher R. Langston, Amelia Waller, Edmund K. |
author_facet | Funk, Christopher Ronald Petersen, Christopher T. Jagirdar, Neera Ravindranathan, Sruthi Jaye, David L. Flowers, Christopher R. Langston, Amelia Waller, Edmund K. |
author_sort | Funk, Christopher Ronald |
collection | PubMed |
description | Clinical trials of chimeric antigen receptor (CAR) T cells in hematologic malignancy associate remissions with two profiles of CAR T cell proliferation kinetics, which differ based upon costimulatory domain. Additional T cell intrinsic factors that influence or predict clinical response remain unclear. To address this gap, we report the case of a 68-year-old woman with refractory/relapsed diffuse large B cell lymphoma (DLBCL), treated with tisagenlecleucel (anti-CD19), with a CD137 costimulatory domain (4-1BB) on an investigational new drug application (#16944). For two months post-infusion, the patient experienced dramatic regression of subcutaneous nodules of DLBCL. Unfortunately, her CAR T exhibited kinetics unassociated with remission, and she died of DLBCL-related sequelae. Serial phenotypic analysis of peripheral blood alongside sequencing of the β-peptide variable region of the T cell receptor (TCRβ) revealed distinct waves of oligoclonal T cell expansion with dynamic expression of immune checkpoint molecules. One week prior to CAR T cell contraction, T cell immunoglobulin mucin domain 3 (Tim-3) and programmed cell death protein 1 (PD-1) exhibited peak expressions on both the CD8 T cell (Tim-3 ≈ 50%; PD-1 ≈ 17%) and CAR T cell subsets (Tim-3 ≈ 78%; PD-1 ≈ 40%). These correlative observations draw attention to Tim-3 and PD-1 signaling pathways in context of CAR T cell exhaustion. |
format | Online Article Text |
id | pubmed-6320786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63207862019-01-07 Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report Funk, Christopher Ronald Petersen, Christopher T. Jagirdar, Neera Ravindranathan, Sruthi Jaye, David L. Flowers, Christopher R. Langston, Amelia Waller, Edmund K. Int J Mol Sci Case Report Clinical trials of chimeric antigen receptor (CAR) T cells in hematologic malignancy associate remissions with two profiles of CAR T cell proliferation kinetics, which differ based upon costimulatory domain. Additional T cell intrinsic factors that influence or predict clinical response remain unclear. To address this gap, we report the case of a 68-year-old woman with refractory/relapsed diffuse large B cell lymphoma (DLBCL), treated with tisagenlecleucel (anti-CD19), with a CD137 costimulatory domain (4-1BB) on an investigational new drug application (#16944). For two months post-infusion, the patient experienced dramatic regression of subcutaneous nodules of DLBCL. Unfortunately, her CAR T exhibited kinetics unassociated with remission, and she died of DLBCL-related sequelae. Serial phenotypic analysis of peripheral blood alongside sequencing of the β-peptide variable region of the T cell receptor (TCRβ) revealed distinct waves of oligoclonal T cell expansion with dynamic expression of immune checkpoint molecules. One week prior to CAR T cell contraction, T cell immunoglobulin mucin domain 3 (Tim-3) and programmed cell death protein 1 (PD-1) exhibited peak expressions on both the CD8 T cell (Tim-3 ≈ 50%; PD-1 ≈ 17%) and CAR T cell subsets (Tim-3 ≈ 78%; PD-1 ≈ 40%). These correlative observations draw attention to Tim-3 and PD-1 signaling pathways in context of CAR T cell exhaustion. MDPI 2018-12-19 /pmc/articles/PMC6320786/ /pubmed/30572564 http://dx.doi.org/10.3390/ijms19124118 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Funk, Christopher Ronald Petersen, Christopher T. Jagirdar, Neera Ravindranathan, Sruthi Jaye, David L. Flowers, Christopher R. Langston, Amelia Waller, Edmund K. Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report |
title | Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report |
title_full | Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report |
title_fullStr | Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report |
title_full_unstemmed | Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report |
title_short | Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report |
title_sort | oligoclonal t cells transiently expand and express tim-3 and pd-1 following anti-cd19 car t cell therapy: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320786/ https://www.ncbi.nlm.nih.gov/pubmed/30572564 http://dx.doi.org/10.3390/ijms19124118 |
work_keys_str_mv | AT funkchristopherronald oligoclonaltcellstransientlyexpandandexpresstim3andpd1followinganticd19cartcelltherapyacasereport AT petersenchristophert oligoclonaltcellstransientlyexpandandexpresstim3andpd1followinganticd19cartcelltherapyacasereport AT jagirdarneera oligoclonaltcellstransientlyexpandandexpresstim3andpd1followinganticd19cartcelltherapyacasereport AT ravindranathansruthi oligoclonaltcellstransientlyexpandandexpresstim3andpd1followinganticd19cartcelltherapyacasereport AT jayedavidl oligoclonaltcellstransientlyexpandandexpresstim3andpd1followinganticd19cartcelltherapyacasereport AT flowerschristopherr oligoclonaltcellstransientlyexpandandexpresstim3andpd1followinganticd19cartcelltherapyacasereport AT langstonamelia oligoclonaltcellstransientlyexpandandexpresstim3andpd1followinganticd19cartcelltherapyacasereport AT walleredmundk oligoclonaltcellstransientlyexpandandexpresstim3andpd1followinganticd19cartcelltherapyacasereport |